A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice

Two years into the COVID-19 pandemic there is still a need for vaccines to effectively control the spread of novel SARS-CoV-2 variants and associated cases of severe disease. Here we report a messenger RNA vaccine directly encoding for a nanoparticle displaying 60 receptor binding domains (RBDs) of...

Descripción completa

Detalles Bibliográficos
Autores principales: Brandys, Pascal, Montagutelli, Xavier, Merenkova, Irena, Barut, Güliz T., Thiel, Volker, Schork, Nicholas J., Trüeb, Bettina, Conquet, Laurine, Deng, Aihua, Antanasijevic, Aleksandar, Lee, Hyun-Ku, Valière, Martine, Sindhu, Anoop, Singh, Gita, Herold, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299372/
https://www.ncbi.nlm.nih.gov/pubmed/35874687
http://dx.doi.org/10.3389/fimmu.2022.912898
Descripción
Sumario:Two years into the COVID-19 pandemic there is still a need for vaccines to effectively control the spread of novel SARS-CoV-2 variants and associated cases of severe disease. Here we report a messenger RNA vaccine directly encoding for a nanoparticle displaying 60 receptor binding domains (RBDs) of SARS-CoV-2 that acts as a highly effective antigen. A construct encoding the RBD of the Delta variant elicits robust neutralizing antibody response, and also provides protective immunity against the Delta variant in a widely used transgenic mouse model. We ultimately find that the proposed mRNA RBD nanoparticle-based vaccine provides a flexible platform for rapid development and will likely be of great value in combatting current and future SARS-CoV-2 variants of concern.

Ejemplares similares